1.
San-Miguel J, Usmani SZ, Mateos M-V, van de Donk NW, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Liu K, Hellemans P, Masterson T, Clemens PL, Luo M, Farnsworth A, Nahi H, Chari A. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica 2021; 106(6):1725-1732; https://doi.org/10.3324/haematol.2019.243790.